{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:01:49Z","timestamp":1794441709987,"version":"4.9.1"},"reference-count":684,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.euroneuro.2015.01.016","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T10:49:18Z","timestamp":1423306158000},"page":"599-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders"],"prefix":"10.1016","volume":"25","author":[{"given":"Mark J.","family":"Millan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy M.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meyer-Lindenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Ove \u00d6gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2015.01.016_bib1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here?","volume":"72","author":"Aan Het Rot","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/515022a","article-title":"After the Berlin Wall: Central Europe up close","volume":"515","author":"Abbott","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1021\/es403688w","article-title":"Longitudinal effects on mental health of moving to greener and less green urban areas","volume":"48","author":"Alcock","year":"2014","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1192\/bjp.bp.113.141424","article-title":"Proportion of patients without mental disorders being treated in mental health services worldwide","volume":"206","author":"Al-Hamzawi","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib6","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.neuron.2012.06.006","article-title":"The brain activity map project and the challenge of functional connectomics","volume":"74","author":"Alivisatos","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000351955","article-title":"Pharmacotherapy of generalized anxiety disorder","volume":"29","author":"Allgulander","year":"2013","journal-title":"Mod. Trends Pharmacopsychiatr."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1017\/S1461145711001738","article-title":"Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?","volume":"15","author":"Alphs","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib9","first-page":"336","article-title":"Rethinking the role of long-acting atypical antipsychotics in the community setting","volume":"27","author":"Altamura","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/NDT.S41387","article-title":"Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder","volume":"15","author":"Alvarez","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/gcb.12700","article-title":"Operationalizing resilience for adaptive coral reef management under global environmental change","volume":"21","author":"Anthony","year":"2015","journal-title":"Glob. Change Biol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1353\/hcr.0.0157","article-title":"Is marketing the enemy of pharmaceutical innovation?","volume":"39","author":"Applbaum","year":"2009","journal-title":"Hastings Cent Rep"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.npp.1301227","article-title":"Tolcapone improves cognition and cortical information processing in normal human subjects","volume":"32","author":"Apud","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib14","first-page":"5","article-title":"An overview of side effects caused by typical antipsychotics","volume":"61","author":"Arana","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2014.11.003","article-title":"Present and future of developmental Neuropsychopharmacology","author":"Arango","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.neuron.2014.02.007","article-title":"Gliotransmitters travel in time and space","volume":"81","author":"Araque","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib1000","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/mp.2013.12","article-title":"An important role for cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors","volume":"19","author":"Arey","year":"2014","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib17","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/mp.2012.150","article-title":"State-dependent changes in hippocampal grey matter in depression","volume":"18","author":"Arnone","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib18","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1038\/sj.npp.1301164","article-title":"Stimulants: therapeutic actions in ADHD","volume":"31","author":"Arnsten","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archpsyc.1996.01830050084013","article-title":"The contribution of alpha2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder","volume":"53","author":"Arnsten","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2013.04.013","article-title":"Developments in the field of antidepressants, where do we go now?","author":"Artigas","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2012.09.006","article-title":"Serotonin receptors involved in antidepressant effects","volume":"137","author":"Artigas","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ypmed.2013.08.017","article-title":"Mental health benefits of neighbourhood green space are stronger among physically active adults in middle-to-older age: evidence from 260,061 Australians","volume":"57","author":"Astell-Burt","year":"2013","journal-title":"Prev. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2013.01.026","article-title":"Recent advances in optogenetics and pharmacogenetics","volume":"1511","author":"Aston-Jones","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0269881109354927","article-title":"MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans","volume":"25","author":"Atack","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1126\/science.133.3450.383","article-title":"Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues","volume":"133","author":"Axelrod","year":"1961","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1963.73700140004017","article-title":"Chlorpromazine: ten years\u05f3 experience","volume":"184","author":"Ayd","year":"1963","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemistry: chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/070674370805300605","article-title":"Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy","volume":"53","author":"Bagby","year":"2008","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/da.20080","article-title":"Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study","volume":"22","author":"Baldomero","year":"2005","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/nedt.2007.3.2.185","article-title":"Role of pregabalin in the treatment of generalized anxiety disorder","volume":"3","author":"Baldwin","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/NDT.S36453","article-title":"Pregabalin for the treatment of generalized anxiety disorder: an update","volume":"9","author":"Baldwin","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.07.027","article-title":"Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety","volume":"58","author":"Ballard","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib33","series-title":"Psychopharmacology Baltmore","author":"Ban","year":"1969"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/YCO.0b013e32835d9efb","article-title":"Polypharmacy for schizophrenia","volume":"26","author":"Ballon","year":"2013","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib35","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenyl-sulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J. Med.Chem."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.drudis.2009.10.001","article-title":"The rise of micropharma","volume":"15","author":"Barden","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1037\/0033-2909.121.1.65","article-title":"Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD","volume":"121","author":"Barkley","year":"1997","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib38","series-title":"Attention-deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment","first-page":"258","author":"Barkley","year":"2006"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib39","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.neuropharm.2012.01.015","article-title":"Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments","volume":"62","author":"Bartzokis","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/mp.2008.106","article-title":"Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole","volume":"15","author":"Basnasr","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib41","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/4551057a","article-title":"The mental wealth of nations","volume":"455","author":"Beddington","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.neuron.2014.10.023","article-title":"Placebo effects: from the neurobiological paradigm to translational implications","volume":"84","author":"Benedetti","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jneumeth.2011.07.009","article-title":"A non-invasive method to isolate the neuronal linage from the nasal epithelium from schizophrenic and bipolar diseases","volume":"201","author":"Benitez-King","year":"2011","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2014.03.035","article-title":"Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy","volume":"161","author":"Bernstein","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib45","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.neubiorev.2012.11.005","article-title":"Psychostimulants and motivated behavior: arousal and cognition","volume":"37","author":"Berridge","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib46","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/bj2060587","article-title":"Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands","volume":"206","author":"Berridge","year":"1982","journal-title":"Biochem. J."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib47","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1176\/appi.ajp.161.10.1798","article-title":"Interaction of COMT (Val(108\/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia","volume":"161","author":"Bertolino","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib48","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s11920-010-0136-4","article-title":"Alpha2 adrenergic receptors and attention-deficit\/hyperactivity disorder","volume":"12","author":"Bidwell","year":"2010","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib49","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/0024-3205(67)90176-2","article-title":"5-hydroxytryptamine uptake by rat brain in vitro","volume":"6","author":"Blackburn","year":"1967","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/npp.2008.151","article-title":"Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles","volume":"34","author":"Blazer","year":"2009","journal-title":"Neuropsychopharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajp.2014.09.001","article-title":"Emerging antidepressants to treat major depressive disorder","volume":"112","author":"Block","year":"2014","journal-title":"Asian J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib52","first-page":"34","article-title":"Toward an integrative understanding of social behavior: new models and new opportunities","volume":"4","author":"Blumstein","year":"2010","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib53","first-page":"105","article-title":"Antipsychotic drugs alter functional connectivity between the medial frontal cortex, hippocampus, and nucleus accumbens as measured by H215O PET","volume":"6","author":"Bolding","year":"2012","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/17460441.2011.584529","article-title":"Can functional magnetic resonance imaging improve success rates in CNS drug discovery?","volume":"6","author":"Borsook","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib55","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study to the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drudis.2011.08.002","article-title":"The role of fragment-based and computational methods in polypharmacology","volume":"17","author":"Bottegoni","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1176\/ajp.94.3.577","article-title":"The behavior of children receiving benzedrine","volume":"94","author":"Bradley","year":"1937","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pbb.2011.11.006","article-title":"The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling","volume":"101","author":"Bradley","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/j.2051-5545.2012.tb00116.x","article-title":"Investigating schizophrenia in a \u201cdish\u201d: possibilities, potential and limitations","volume":"11","author":"Bray","year":"2012","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib60","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.chc.2013.06.003","article-title":"Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings","volume":"22","author":"Brent","year":"2013","journal-title":"Child Adolesc. Clin. N. Am."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ddr.20285","article-title":"Adaptivity in drug discovery and development","volume":"70","author":"Bretz","year":"2009","journal-title":"Drug Develop. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.euroneuro.2009.01.012","article-title":"Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants. Committee for Medicinal Products for Human Use","volume":"19","author":"Broich","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib63","first-page":"167261","article-title":"Prenatal infection and schizophrenia: a review of epidemiologic and translational studies","author":"Brown","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib64","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1176\/ajp.153.10.1293","article-title":"Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders","volume":"153","author":"Brown","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib65","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1038\/npp.2011.159","article-title":"Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety","volume":"36","author":"Browning","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib66","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neubiorev.2008.09.002","article-title":"Default-mode brain dysfunction in mental disorders: a systematic review","volume":"33","author":"Broyd","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.neubiorev.2005.08.001","article-title":"Theory of mind evolution, ontogeny, brain mechanisms and psychopathology","volume":"30","author":"Br\u00fcne","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib68","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.tree.2013.02.004","article-title":"Condition dependence, developmental plasticity, and cognition: implications for ecology and evolution","volume":"28","author":"Buchanan","year":"2013","journal-title":"Trends Ecol. Evol."},{"issue":"Spring","key":"10.1016\/j.euroneuro.2015.01.016_bib69","first-page":"70","article-title":"How digital innovation and collaboration is driving a global demand for effective reporting in research funding","author":"Buck","year":"2014","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib70","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.neuron.2012.06.002","article-title":"Psychopathology and the human connectome: toward a transdiagnostic model of risk for mental illness","volume":"74","author":"Buckholtz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib71","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1600-0447.2005.00513.x","article-title":"Comorbidity of physical and mental disorders and the effect on work-loss days","volume":"111","author":"Buist-Bouwman","year":"2005","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib72","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.pnpbp.2006.01.006","article-title":"Psychosis: a costly by-product of social brain evolution in Homo sapiens","volume":"30","author":"Burns","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib73","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrd3811","article-title":"DSM-5 and clinical trials in psychiatry: challenges to come?","volume":"11","author":"Butlen-Ducuing","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib74","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1358\/dnp.2010.23.1.1437303","article-title":"European medicines agency support mechanisms fostering orphan drug development","volume":"23","author":"Butlen-Ducuing","year":"2010","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib76","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5694\/j.1326-5377.1949.tb36912.x","article-title":"Lithium salts in the treatment of psychotic excitement","volume":"36","author":"Cade","year":"1949","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4088\/JCP.v60n0203","article-title":"A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression","volume":"60","author":"Calabrese","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib78","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(08)61762-6","article-title":"Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis","volume":"373","author":"Cameron","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jad.2014.04.078","article-title":"Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder","volume":"166","author":"Cameron","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biopsych.2014.05.023","article-title":"Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk","volume":"77","author":"Cannon","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib81","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-079X.2011.00962.x","article-title":"Melatonin and its analogs in insomnia and depression","volume":"52","author":"Cardinali","year":"2012","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib82","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.peptides.2012.03.031","article-title":"Acute ghrelin administration reverses depressive-like behavior induced by bilateral olfactory bulbectomy in mice","volume":"35","author":"Carlini","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib83","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0014-2999(69)90113-7","article-title":"Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine","volume":"5","author":"Carlsson","year":"1969","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib84","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1126\/science.127.3296.471","article-title":"On the presence of 3-hydroxytyramine in brain","volume":"127","author":"Carlsson","year":"1958","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib85","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse","volume":"20","author":"Carlsson","year":"1963","journal-title":"Brain Acta Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib86","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/sj.npp.1301639","article-title":"The evolution of drug development in schizophrenia: past issues and future opportunities","volume":"33","author":"Carpenter","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib87","first-page":"47","article-title":"Gene editing re-writing genomes with targetable nucleases","author":"Carroll","year":"2013","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib88","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-12-420118-7.00005-6","article-title":"Bupropion and bupropion analogs as treatments for CNS disorders","volume":"69","author":"Carroll","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib89","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/nrn3621","article-title":"DSM-5 and RDoC: progress in psychiatry research?","volume":"14","author":"Casey","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib90","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.1083968","article-title":"Influence of life stress on depression: moderation by a polymorphism in the 5-HT gene","volume":"301","author":"Caspi","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.euroneuro.2015.01.016_bib800","first-page":"CD007813","article-title":"Amphetamines for attention deficit hyperactivity disorder in adults","volume":"15","author":"Castells","year":"2011","journal-title":"Cochrane Database Syst Rev. Jun"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib91","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.psyneuen.2011.12.014","article-title":"Personality traits in rats predict vulnerability and resilience to developing stress-induced depression-like behaviors, HPA axis hyper-reactivity and brain changes in pERK1\/2 activity","volume":"37","author":"Castro","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib92","first-page":"378","article-title":"Molecular imaging PET and SPECT approaches for improving productivity of antipsychotic drug discovery and development","volume":"20","author":"Catafau","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib93","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nrd2981","article-title":"APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use","volume":"8","author":"Cavalla","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib94","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drudis.2012.08.003","article-title":"Something\u05f3s got to give: psychiatric disease on the rise and novel drug development on the decline","volume":"18","author":"Chandler","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib95","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/0269881112444941","article-title":"Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment","volume":"26","author":"Chaudhry","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib96","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/425589","article-title":"Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain","volume":"75","author":"Chen","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib97","first-page":"19","article-title":"Azapirones for generalized anxiety disorder","author":"Chessick","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib98","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.euroneuro.2012.08.012","article-title":"The cost of mental disorders in France","volume":"23","author":"Chevreul","year":"2013","journal-title":"Eur. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib99","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/nrd2999","article-title":"Targeting protein kinases in central nervous system disorders","volume":"8","author":"Chico","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib100","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nature13800","article-title":"A three-dimensional human neural cell culture model of Alzheimer\u05f3s disease","volume":"515","author":"Choi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib101","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.111.005512","article-title":"Therapeutic potential of mood stabilizers lithium and Valproic acid: beyond bipolar disorder","volume":"65","author":"Chiu","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"ID460549","key":"10.1016\/j.euroneuro.2015.01.016_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/460549","article-title":"Ghrelin\u05f3s roles in stress, mood, and anxiety regulation","volume":"2010","author":"Chuang","year":"2010","journal-title":"Int. J. Peptides"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib103","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib104","first-page":"10","article-title":"Duloxetine versus other anti-depressive agents for depression","author":"Cipriani","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.euroneuro.2012.04.008","article-title":"Burden of psychiatric disorders in the pediatric population","volume":"23","author":"Clavenna","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib106","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijdevneu.2010.08.007","article-title":"Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia","volume":"29","author":"Clay","year":"2011","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib107","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-012-2845-3","article-title":"Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine","volume":"225","author":"Clifton","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib108","first-page":"71","article-title":"The science of well-being: an integrated approach to mental health and its disorders","volume":"5","author":"Cloninger","year":"2006","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib109","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.tree.2010.08.002","article-title":"Individuals and populations: the role of long-term, individual-based studies of animals in ecology and evolutionary biology","volume":"25","author":"Clutton-Brock","year":"2010","journal-title":"Trends Ecol. Evol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib110","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jama.1964.03070180046007","article-title":"Therapeutic efficacy of antidepressant drugs: a review","volume":"190","author":"Cole","year":"1964","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib111","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2011.02.010","article-title":"Variable global dysconnectivity and individual differences in schizophrenia","volume":"70","author":"Cole","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib112","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/da.20620","article-title":"Barriers to treatment seeking for anxiety disorders: initial data on the role of mental health literacy","volume":"27","author":"Coles","year":"2010","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib113","doi-asserted-by":"crossref","first-page":"e1001434","DOI":"10.1371\/journal.pmed.1001434","article-title":"Grand challenges in global mental health: integration in research, policy, and practice","volume":"10","author":"Collins","year":"2013","journal-title":"PLoS Med."},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib114","first-page":"26","article-title":"Outsourced kinase profiling services \u2013 adding value to in-house kinase programmes","author":"Comley","year":"2013","journal-title":"Drug Discov. World"},{"issue":"Spring","key":"10.1016\/j.euroneuro.2015.01.016_bib115","first-page":"62","article-title":"The current status of non-biopharma drug discovery","author":"Comley","year":"2014","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib116","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nrd4308","article-title":"Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders","volume":"13","author":"Conn","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib117","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/14728214.2012.660146","article-title":"Emerging drugs for major depressive disorder","volume":"17","author":"Connolly","year":"2012","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib118","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1517\/14656566.2014.930437","article-title":"Guanfacine extended release for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"15","author":"Connor","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib119","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/dneu.22096","article-title":"Increasing our understanding of human cognition through the study of Fragile X Syndrome","volume":"74","author":"Cook","year":"2014","journal-title":"Dev. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib120","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","article-title":"ADHD drugs and serious cardiovascular events in children and young adults","volume":"365","author":"Cooper","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib121","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaac.2010.12.014","article-title":"Cumulative prevalence of psychiatric disorders by young adulthood: a prospective cohort analysis form the great smoky mountain study","volume":"50","author":"Copeland","year":"2011","journal-title":"J. Am. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib122","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1192\/bjp.113.504.1237","article-title":"The biochemistry of affective disorders","volume":"113","author":"Coppen","year":"1967","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib123","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1586\/ern.10.101","article-title":"Current concept of anxiety: implications form Darwin to the DSM-V for the diagnosis of generalized anxiety disorder","volume":"10","author":"Corr\u00eaa Coutinho","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib124","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4088\/JCP.11r07064","article-title":"Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics","volume":"72","author":"Correll","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib125","first-page":"79","article-title":"Fluorescence lifetime assays","author":"Cotton","year":"2013","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib126","first-page":"142","article-title":"Iproniazid (marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases","volume":"8","author":"Crane","year":"1957","journal-title":"Psychiatry Res. Rep. Am. Psychiatr. Assoc."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib127","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib128","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(12)62129-1","article-title":"Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis","volume":"381","author":"Cross-Disorder Group of the Psychiatric Genomics Consortium","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cpr.2009.09.003","article-title":"Psychotherapy for chronic major depression and dysthymia: a meta-analysis","volume":"30","author":"Cuijpers","year":"2010","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib130","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jalz.2008.12.003","article-title":"Defining and labeling disease-modifying treatments for Alzheimer\u05f3s disease","volume":"5","author":"Cummings","year":"2009","journal-title":"Alzheimer\u05f3s Dementia"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/10673220600748536","article-title":"Coalescence of psychiatry, neurology, and neuropsychology: from theory to practice","volume":"14","author":"Cunningham","year":"2006","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib132","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/schbul\/sbq108","article-title":"Toward new approaches to psychotic disorders: the NIMH research domain criteria project","volume":"36","author":"Cuthbert","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib133","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1741-7015-11-126","article-title":"Toward the future of psychiatric diagnosis: the seven pillars of RDoC","volume":"11","author":"Cuthbert","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib134","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/wps.20087","article-title":"The RDoC framework: facilitating transition from ICD\/DSM to dimensional approaches that integrate neuroscience and psychopathology","volume":"13","author":"Cuthbert","year":"2014","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003495-199856020-00005","article-title":"Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder","volume":"56","author":"Cyr","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib136","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.euroneuro.2012.04.017","article-title":"Antidepressants act directly on astrocytes: evidence and functional consequences","volume":"23","author":"Czeh","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib137","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.4155\/fmc.14.60","article-title":"The essential roles of chemistry in high-throughput screening triage","volume":"6","author":"Dahlin","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib138","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-244X-13-279","article-title":"What is the potential for social networks and support to enhance future telehealth interventions for people with a diagnosis of schizophrenia: a critical interpretive synthesis","volume":"13","author":"Daker-White","year":"2013","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib139","first-page":"1","article-title":"Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons","volume":"232","author":"Dahlstr\u00f6m","year":"1964","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib140","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11920-009-0074-1","article-title":"Melatonin, circadian rhythms, and the clock genes in bipolar disorder","volume":"11","author":"Dallaspezia","year":"2009","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib141","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/1087054707310878","article-title":"ADHD in adults: a review of the literature","volume":"11","author":"Davidson","year":"2008","journal-title":"J. Atten. Disord."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib900","unstructured":"Davidson, J.R., 2006. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 67: Suppl 12, 20-26."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib142","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1124\/mol.58.4.756","article-title":"Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptors","volume":"58","author":"Davies","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib143","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrd2825","article-title":"The microeconomics of personalized medicine: today\u05f3s challenge and tomorrow\u05f3s promise","volume":"8","author":"Davis","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1747-5341-6-8","article-title":"Should we treat depression with drugs or psychological interventions? A reply to loannidis","volume":"6","author":"Davis","year":"2011","journal-title":"Philos. Ethics Humanit. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900009871","article-title":"Development of subtype selective GABAA modulators","volume":"10","author":"Dawson","year":"2005","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib146","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/00048670802534416","article-title":"Is schizophrenia the price of human central nervous system complexity?","volume":"43","author":"Dean","year":"2009","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib147","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1017\/S1461145713001077","article-title":"Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP think tank","volume":"17","author":"Dean","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib148","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.neuron.2014.08.034","article-title":"Great expectations: using whole-brain computational connectomics for understanding neuropsychiatric disorders","volume":"84","author":"Deco","year":"2014","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.euroneuro.2015.01.016_bib149","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrd3140","article-title":"Agomelatine, the first melatonergic antidepressant: discovery, characterization and development","volume":"2010","author":"De Bodinat","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib150","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.tics.2010.06.009","article-title":"Can social interaction constitute social cognition?","volume":"14","author":"De Jaegher","year":"2010","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib151","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00213-008-1177-9","article-title":"S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models","volume":"199","author":"Dekeyne","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib152","first-page":"497","article-title":"Le traitement des psychoses par une m\u00e9thode neurolytique d\u00e9riv\u00e9e d\u00b4hibernoth\u00e9rapie, le 4560R.P. utilis\u00e9 seul en cure prolong\u00e9e et continue","volume":"50","author":"Delay","year":"1952","journal-title":"C.R. Congr. ali\u00e9n. Neur. France"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib153","first-page":"112","article-title":"Utilisation en th\u00e9rapeutique psychiatrique d\u05f3une ph\u00e9nothiazine d\u05f3action centrale \u00e9lective (4560 RP)","volume":"2","author":"Delay","year":"1952","journal-title":"Ann. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib154","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200225040-00004","article-title":"Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview","volume":"25","author":"De Ponti","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib155","first-page":"23","article-title":"Augmenting psychoeducation with a mobile intervention for bipolar disorder: A randomized controlled trial","volume":"174C","author":"Depp","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib156","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nrn2345","article-title":"Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms","volume":"9","author":"DeRubeis","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib157","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbi.2012.02.010","article-title":"Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene \u00d7 environment interaction","volume":"26","author":"Desbonnet","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib158","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/npp.2008.115","article-title":"Novel therapeutic modalities to address nondrugable protein interaction targets","volume":"34","author":"De Souza","year":"2009","journal-title":"Neuropsychopharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib159","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrg3116","article-title":"Genomically humanized mice: technologies and promises","volume":"13","author":"Devoy","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib801","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1517\/14656566.2010.531009","article-title":"Lisdexampfetamine dimesylate: a new option in stimulant treatment for ADHD","volume":"11","author":"Dew","year":"2010","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib160","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2174\/1389450111314110011","article-title":"Talking to the synapse: how antidepressants can target glial cells to reshape brain circuits","volume":"14","author":"Di Benedetto","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib161","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1460-9568.2010.07596.x","article-title":"Consensus document on European brain research","volume":"33","author":"Di Luca","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib162","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mde.1360","article-title":"The cost of biopharmaceutical R&D: is biotech different?","volume":"28","author":"Di Masi","year":"2007","journal-title":"Manage. Decis. Econ."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib163","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1749-6632.2011.06039.x","article-title":"G protein-coupled receptor modulation with pepducins: moving closer to the clinic","volume":"1226","author":"Dimond","year":"2011","journal-title":"Ann. NY Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib164","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/2013.jamapsychiatry.5","article-title":"Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging","volume":"70","author":"Doehrmann","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib165","doi-asserted-by":"crossref","unstructured":"Doherty, J.L., Owen, M.J., 2014. Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice. Genome Med. 2014 Apr 28;6(4):29. 10.1186\/gm546","DOI":"10.1186\/gm546"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib166","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd4411","article-title":"Massive schizophrenia genomics study offers new drug directions","volume":"13","author":"Dolgin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib167","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1037\/h0082313","article-title":"Stop, look, and listen: The problem of sustained attention and impulse control in hyperactive and normal children","volume":"4","author":"Douglas","year":"1972","journal-title":"Canad. J. Behav. Sci."},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib168","first-page":"9","article-title":"The challenges of the changing drug discovery model","author":"Downs","year":"2012","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib169","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.euroneuro.2010.09.004","article-title":"An introduction to adaptive designs and adaptation in CNS trials","volume":"21","author":"Dragalin","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib170","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1359-6446(03)02690-4","article-title":"Strategic trends in the drug industry","volume":"8","author":"Drews","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib171","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2205","article-title":"What\u05f3s in a number?","volume":"5","author":"Drews","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib172","first-page":"1036","article-title":"Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence","volume":"37","author":"D\u05f3Souza","year":"2012"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib173","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.npp.1301178","article-title":"The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders","volume":"32","author":"Du","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib174","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.2174\/156802612805289908","article-title":"Transcranial magnetic stimulation in schizophrenia: the contribution of neuroimaging","volume":"12","author":"Du","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib175","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.neubiorev.2012.03.003","article-title":"Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia","volume":"37","author":"Dudchenko","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib176","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tins.2011.11.004","article-title":"Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents","volume":"35","author":"Duman","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib177","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.biopsych.2008.05.015","article-title":"The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia","volume":"64","author":"Durstewitz","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib178","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S1461145711001702","article-title":"mTOR activation is required for the antidepressant effects of mGluR2\/3 blockade","volume":"15","author":"Dwyer","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib179","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.neuron.2008.12.007","article-title":"Reversing neurodevelopmental disorders in adults","volume":"60","author":"Ehninger","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib180","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nrd4129","article-title":"The risks of risk aversion in drug regulation","volume":"12","author":"Eichler","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib181","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.expneurol.2014.02.006","article-title":"Molecular mechanisms linking neuroinflammation and neurodegeneration in MS","volume":"262PA","author":"Ellwardt","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib182","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1126\/science.1098410","article-title":"The mentality of crows: convergent evolution of intelligence in corvids and apes","volume":"306","author":"Emery","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib183","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev.psych.60.110707.163526","article-title":"Comparative social cognition","volume":"60","author":"Emery","year":"2009","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib184","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1098\/rspb.2010.0973","article-title":"Parasite prevalence and the worldwide distribution of cognitive ability","volume":"277","author":"Eppig","year":"2010","journal-title":"Proc. R. Soc. B"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib185","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in medicine: minimize, maximize or personalize?","volume":"12","author":"Enck","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib187","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/bmm.13.135","article-title":"Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia","volume":"8","author":"English","year":"2014","journal-title":"Biomark. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib188","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.108.143420","article-title":"Challenges in the search for drugs to treat central nervous system disorders","volume":"329","author":"Enna","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib189","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuron.2012.12.011","article-title":"Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits in vivo","volume":"77","author":"Espuny-Camacho","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib190","doi-asserted-by":"crossref","first-page":"427","DOI":"10.31887\/DCNS.2009.11.4\/kevers","article-title":"Personalized medicine in psychiatry: ethical challenges and opportunities","volume":"11","author":"Evers","year":"2009","journal-title":"Dialog. Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib191","doi-asserted-by":"crossref","first-page":"c4737","DOI":"10.1136\/bmj.c4737","article-title":"Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials","volume":"341","author":"Eyding","year":"2010","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib192","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/0006-2952(86)90285-6","article-title":"Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors","volume":"35","author":"Fagervall","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib193","first-page":"456","article-title":"Diagnosis and management of ADHD in children","volume":"90","author":"Felt","year":"2014","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib194","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1021\/jm049632c","article-title":"Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents","volume":"48","author":"Fern\u00e1ndez","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00131746-200407000-00005","article-title":"The role of monoamine oxidase inhibitors in current psychiatric practice\u201c","volume":"10","author":"Fiedorowicz","year":"2004","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib196","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.clinthera.2008.05.006","article-title":"Evolution of the treatment of attention-deficit-hyperactivity disorder in children: a review","volume":"30","author":"Findling","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib197","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145704004675","article-title":"Evidence-based pharmacotherapy of obsessive-compulsive disorder","volume":"8","author":"Fineberg","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib198","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pneurobio.2014.02.004","article-title":"What is normal in normal aging? Effects of aging, amyloid and Alzheimer\u05f3s disease on the cerebral cortex and the hippocampus. Alzheimer\u05f3s Disease Neuroimaging Initiative","volume":"117","author":"Fjell","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib199","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00213-002-1060-z","article-title":"Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe","volume":"162","author":"Fleischhacker","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib200","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/14737175.6.9.1249","article-title":"Bupropion: pharmacology and therapeutic applications","volume":"6","author":"Foley","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib201","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2012.08.015","article-title":"The involvement of Reelin in neurodevelopmental disorders","volume":"68","author":"Folsom","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib202","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00213-014-3664-5","article-title":"Ketamine administration in depressive disorders: a systematic review and meta-analysis","volume":"231","author":"Fond","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib203","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1093\/schbul\/sbu011","article-title":"Studying hallucinations within the NIMH RDoC framework","volume":"40","author":"Ford","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2014.02.011","article-title":"Connectomics: a new paradigm for understanding brain disease","author":"Fornito","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib205","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/cercor\/bhr130","article-title":"Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex","volume":"22","author":"Fossat","year":"2012","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib206","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tins.2013.01.005","article-title":"Gut-brain axis: how the microbiome influences anxiety and depression","volume":"36","author":"Foster","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib207","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","article-title":"Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders","volume":"24","author":"Foussias","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib208","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.biopsych.2012.04.028","article-title":"Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate","volume":"72","author":"Fox","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib209","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/11207550-000000000-00000","article-title":"Vilazodone in major depressive disorder","volume":"25","author":"Frampton","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib210","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/npp.2010.96","article-title":"Neurogenetics and pharmacology of learning, motivation, and cognition","volume":"36","author":"Franck","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib211","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature12929","article-title":"De novo mutations in schizophrenia implicate synaptic networks","volume":"506","author":"Fromer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib212","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/070674371305800904","article-title":"Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift","volume":"58","author":"Fu","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib213","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/med.2610110103","article-title":"Fluoxetine, a selective inhibitor of serotonin uptake","volume":"11","author":"Fuller","year":"1991","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib214","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamapsychiatry.2013.269","article-title":"The psychosis high-risk state: a comprehensive state-of-the-art review","volume":"70","author":"Fusar-Poli","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib215","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.drudis.2008.12.011","article-title":"Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations","volume":"14","author":"Gabrielsson","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib216","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based method for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib217","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1515\/dmdi-2013-0002","article-title":"Applying systems biology in drug discovery and development","volume":"28","author":"Galizzi","year":"2013","journal-title":"Drug Metabol. Drug Interact."},{"issue":"Summer","key":"10.1016\/j.euroneuro.2015.01.016_bib218","first-page":"37","article-title":"The CRISPR\/Cas9 system: cutting a path for rapid generation of more translational animal models","author":"Gamber","year":"2014","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib219","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/157488411796151156","article-title":"Determinants of medicine-taking in psychiatric patients","volume":"6","author":"Garcia-Ribera","year":"2011","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib220","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00148581-200911030-00005","article-title":"Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents","volume":"11","author":"Garnock-Jones","year":"2009","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib221","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.euroneuro.2013.12.004","article-title":"Functionally altered neurocircuits in a rat model of treatment-resistant depression show prominent role of the habenula","volume":"24","author":"Gass","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib222","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-801311-3.00005-6","article-title":"Epigenetics of schizophrenia: an open and shut case","volume":"115","author":"Gavin","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib223","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ddr.20403","article-title":"Mechanistic disease modeling as a useful tool for improving CNS drug research and development","volume":"72","author":"Geerts","year":"2011","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib224","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/13543784.2012.633510","article-title":"\u03b17 nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer\u05f3s disease","volume":"21","author":"Geerts","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib225","doi-asserted-by":"crossref","first-page":"e49732","DOI":"10.1371\/journal.pone.0049732","article-title":"Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response","volume":"7","author":"Geerts","year":"2012","journal-title":"PLos One"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib226","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.4088\/JCP.v69n1001","article-title":"The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies","volume":"69","author":"Gelenberg","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib227","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1176\/appi.ajp.2012.12020237","article-title":"Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies","volume":"170","author":"GENDEP Investigators","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib228","doi-asserted-by":"crossref","first-page":"783","DOI":"10.5694\/j.1326-5377.1956.tb35808.x","article-title":"The treatment of shock-dependency by pharmacological agents","volume":"1","author":"Gershon","year":"1956","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib229","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jneumeth.2011.08.040","article-title":"Simultaneous quantification of d- vs. l-serine, taurine, kynurenate, phosphoethanolamine and diverse amino acids in frontocortical dialysates of freely-moving rats: differential modulation by N-methyl-D-aspartate (NMDA) and other pharmacological agents","volume":"202","author":"Gobert","year":"2011","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib230","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/clpt.2011.321","article-title":"The innovative medicines initiative: a European response to the innovation challenge","volume":"91","author":"Goldman","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib1001","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1017\/S1461145714000789","article-title":"Making sense of deep sequencing","volume":"17","author":"Goldman","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib231","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cpr.2014.06.003","article-title":"A review of selected candidate endophenotypes for depression","volume":"34","author":"Goldstein","year":"2014","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib232","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharmthera.2012.02.003","article-title":"Stress management at the ER: regulators of ER stress-induced apoptosis","volume":"134","author":"Gorman","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib233","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/sj.npp.1300731","article-title":"Glycogen Synthase Kinase-3: a putative molecular target for lithium mimetic drugs","volume":"30","author":"Gould","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib234","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/jamainternmed.2013.13018","article-title":"Mediation programs for psychological stress and well-being: a systematic review and meta-analysis","volume":"174","author":"Goyal","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib235","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.tcb.2011.07.003","article-title":"Postsynaptic proSAP\/shank scaffolds in the cross-hairs of synaptopathies","volume":"21","author":"Grabrucker","year":"2011","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib236","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0026-895X(25)08760-7","article-title":"Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin","volume":"47","author":"Granger","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib237","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/schbul\/sbr155","article-title":"Mobile Assessment and Treatment for Schizophrenia (MATS): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations","volume":"38","author":"Granholm","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib238","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/gbe\/evt028","article-title":"On the immortality of television sets: \u201cfunction\u201d in the human genome according to the evolution-free Gospel of ENCODE","volume":"5","author":"Graur","year":"2013","journal-title":"Genome Biol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib239","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/npp.2012.125","article-title":"The dynamics of DNA methylation in schizophrenia and related psychiatric disorders","volume":"38","author":"Grayson","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib241","doi-asserted-by":"crossref","first-page":"e5639","DOI":"10.1371\/journal.pone.0005639","article-title":"Failure to replicate a genetic association may provide important clues about genetic architecture","volume":"4","author":"Greene","year":"2009","journal-title":"PLoS One"},{"issue":"Winter","key":"10.1016\/j.euroneuro.2015.01.016_bib242","first-page":"22","article-title":"The repositioning revolution: save me from extinction to find me pastures new","volume":"14","author":"Green","year":"2013","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib806","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neuroscience.2012.04.044","article-title":"Dendritic spine pathology in schizophrenia","volume":"251","author":"Glausier","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib243","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00787-013-0498-3","article-title":"Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges","volume":"23","author":"Glennon","year":"2014","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib244","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tree.2014.06.004","article-title":"Comparative cognition for conservationists","volume":"29","author":"Greggor","year":"2014","journal-title":"Trends Ecol. Evol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib245","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrd4075","article-title":"50 years of hurdles and hope in anxiolytic drug discovery","volume":"12","author":"Griebel","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib246","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1176\/ajp.152.2.298b","article-title":"Origin of stimulant use for treatment of attention deficit disorder [letter]","volume":"152","author":"Gross","year":"1995","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib247","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/bdi.12125","article-title":"Reduced burden of very large and rare CNVs in bipolar affective disorder","volume":"15","author":"Grozeva","year":"2013","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib248","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties","volume":"171","author":"Guardiola-Lemaitre","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib249","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","article-title":"Cost of disorders of the brain in Europe 2010","volume":"21","author":"Gustavsson","year":"2011","journal-title":"Eur. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib250","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrg2735","article-title":"Personalized genomic information: preparing for the future of genetic medicine","volume":"11","author":"Guttmacher","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib251","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib252","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0014-2999(81)90172-2","article-title":"Effects of antidepressant drugs on different receptors in the brain","volume":"70","author":"Hall","year":"1981","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib253","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jama.2014.3839","article-title":"European-led project strives to simulate the human brain","volume":"311","author":"Hampton","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib254","first-page":"252","article-title":"Structured evaluation of rodent behavioral tests used in drug discovery research","volume":"8","author":"H\u00e5nell","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib255","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/09638237.2011.608746","article-title":"Mobile mental health: review of the emerging field and proof of concept study","volume":"20","author":"Harrison","year":"2011","journal-title":"J. Ment. Health"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib257","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.neuro.051508.135335","article-title":"The neurobiology of individual differences in complex behavioral traits","volume":"32","author":"Hariri","year":"2009","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib258","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1177\/0269881110367722","article-title":"Efficacy markers in depression","volume":"25","author":"Harmer","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib259","first-page":"1","article-title":"ROAMER: roadmap for mental health research in Europe","volume":"23","author":"Haro","year":"2014"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib260","first-page":"388","article-title":"The genetics of cognitive ability and cognitive ageing in healthy older people","volume":"15","author":"Harris","year":"2011","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2013.02.005","article-title":"The current and potential impact of genetics and genomics on neuropsychopharmacology","author":"Harrison","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib262","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/09638237.2011.608746","article-title":"Mobile mental health: review of the emerging field and proof of concept study","volume":"20","author":"Harrison","year":"2011","journal-title":"J. Ment. Health"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib263","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neubiorev.2007.05.012","article-title":"Large brains and cognition: where do elephants fit in?","volume":"32","author":"Hart","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib264","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2012.05.006","article-title":"Network analysis has diverse roles in drug discovery","volume":"17","author":"Hasan","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib265","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","article-title":"Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders","volume":"263","author":"Hashimoto","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib266","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.biopsych.2005.11.006","article-title":"Toward constructing an endophenotype strategy for bipolar disorders","volume":"60","author":"Hasler","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib267","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/509146a","article-title":"Universities seek to boost industry partnerships: as drug companies shift focus, academia ramps up its role in bringing discoveries to market","volume":"509","author":"Hayden","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib268","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fncel.2013.00218","article-title":"Neuroplasticity and the next wave of antidepressant strategies","volume":"7","author":"Hayley","year":"2013","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib802","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0269881113482532","article-title":"Amphetamine, past and present \u2013 a pharmacological and clinical perspective","volume":"27","author":"Heal","year":"2013","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib269","series-title":"The Antidepressant Era","first-page":"317","author":"Healy","year":"1997"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib270","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1749-6632.2009.05149.x","article-title":"Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders","volume":"1187","author":"Heidbreder","year":"2010","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib271","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.drudis.2008.11.011","article-title":"G-protein-coupled receptor-focused drug discovery using a target class platform approach","volume":"14","author":"Heilker","year":"2009","journal-title":"Drug Discov. Today"},{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2015.01.016_bib272","first-page":"S5","article-title":"The history of valproate in clinical neuroscience","volume":"37","author":"Henry","year":"2003","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib273","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02741459","article-title":"The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes","volume":"18","author":"Hevers","year":"1998","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib274","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1254\/jphs.12R15CP","article-title":"Behavioral phenotypes in schizophrenic animal models with multiple combinations of genetic and environmental factors","volume":"121","author":"Hida","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib275","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neubiorev.2014.11.010","article-title":"Molecular imaging of neuropsychiatric symptoms in Alzheimer\u05f3s and Parkinson\u05f3s disease","volume":"49","author":"Hirao","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib276","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YCO.0000000000000055","article-title":"Social cognition in serious mental illness","volume":"27","author":"Hoertnagl","year":"2014","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib277","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tree.2014.07.008","article-title":"An evolutionary framework for studying mechanisms of social behavior","volume":"29","author":"Hofmann","year":"2014","journal-title":"Trends Ecol. Evol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib278","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jamapsychiatry.2014.1054","article-title":"Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial","volume":"71","author":"Hollon","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib279","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-3956(98)90056-5","article-title":"The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety","volume":"33","author":"Holsboer","year":"1999","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib280","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/B978-0-444-52002-9.00041-3","article-title":"Brain stimulation therapies for neuropsychiatric disease","volume":"106","author":"Holtzheimer","year":"2012","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib281","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00702-014-1338-4","article-title":"Heterogeneity and individuality: microRNAs in mental disorders","volume":"122","author":"Hommers","year":"2015","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib282","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1523\/JNEUROSCI.0910-08.2008","article-title":"Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo","volume":"28","author":"Honey","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib283","series-title":"ACS Chem. Biol","article-title":"Time-resolved FRET binding assay to investigate hetero-oligomer binding properties: proof of concept with dopamine D1\/D3 heterodimer","author":"Hounsou","year":"2014"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib284","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1476-5381.2009.00359.x","article-title":"Disrupting specific PDZ domain-mediated interactions for therapeutic benefit","volume":"158","author":"Houslay","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib285","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1471-2164-12-S5-S11","article-title":"Predicting adverse side effects of drugs","volume":"12","author":"Huang","year":"2011","journal-title":"BMC Genom."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib286","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2010.07.016","article-title":"Structure-based drug discovery and protein targets in the CNS","volume":"60","author":"Hubbard","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib287","doi-asserted-by":"crossref","first-page":"29","DOI":"10.31887\/DCNS.2007.9.1\/jchuffman","article-title":"Neuropsychiatric consequences of cardiovascular medications","volume":"9","author":"Huffman","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib288","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1021\/jm2010332","article-title":"Rational approaches to improving selectivity in drug design","volume":"55","author":"Huggins","year":"2012","journal-title":"J. Med. Chem."},{"issue":"Spring","key":"10.1016\/j.euroneuro.2015.01.016_bib289","first-page":"9","article-title":"Collaboration for innovation is the new mantra for the pharmaceutical industry","author":"Hunter","year":"2014","journal-title":"Drug Discov.World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib290","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/hlca.19670500618","article-title":"11-Amino-5H-dibenzo[b, e]-1, 4-diazepine. 10. Mitteilung \u00fcber sieben gliedrige Heterocyclen","volume":"50","author":"Hunziker","year":"1967","journal-title":"Helvet. Chim. Acta"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib291","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrn2218","article-title":"Can neuroscience be integrated into the DSM-V?","volume":"8","author":"Hyman","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib292","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.clinpsy.3.022806.091532","article-title":"The diagnosis of mental disorders: the problem of reification","volume":"6","author":"Hyman","year":"2010","journal-title":"Annu. Rev. Clin."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib293","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib294","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib295","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/clpt.2011.38","article-title":"The use of induced pluripotent stem cells in drug development","volume":"89","author":"Inoue","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib296","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.biopsych.2007.10.001","article-title":"From animal models to model animals","volume":"62","author":"Insel","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib1002","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/mp.2013.168","article-title":"Brain somatic mutations: the dark matter of psychiatric genetics?","volume":"19","author":"Insel","year":"2014","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib297","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/appi.ajp.2014.14020138","article-title":"The NIMH research domain criteria (RDoC) project: precision medicine for psychiatry","volume":"171","author":"Insel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib298","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib299","doi-asserted-by":"crossref","first-page":"e1001747","DOI":"10.1371\/journal.pmed.1001747","article-title":"How to make more published research true","volume":"11","author":"Ioannidis","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib300","doi-asserted-by":"crossref","first-page":"171","DOI":"10.31887\/DCNS.2014.16.2\/rcohen","article-title":"Patient-reported outcomes before and after treatment of major depressive disorder","volume":"16","author":"IsHak","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib301","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Expert Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib302","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib303","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-013-1185-7","article-title":"Cerebral amyloid PET imaging in Alzheimer\u05f3s disease","volume":"126","author":"Jack","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib304","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.tig.2010.08.006","article-title":"Gene targeting in the rat: advances and opportunities","volume":"28","author":"Jacob","year":"2010","journal-title":"Trends Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib305","first-page":"841","volume":"17","author":"Janssen","year":"1967","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib306","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00415-009-0084-2","article-title":"Multiple sclerosis patients\u2019 benefic-risk preferences: serious adverse event risks versus treatment efficacy","volume":"256","author":"Johnson","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib307","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib308","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1037\/a0025957","article-title":"Mental health literacy: empowering the community to take action for better mental health","volume":"67","author":"Jorm","year":"2012","journal-title":"Am. Psychol."},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib309","first-page":"9","article-title":"Principles for winning digital health strategies","author":"Kaltenbach","year":"2014","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib310","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1017\/S0033291711003059","article-title":"Transcranial direct current stimulation in the treatment of major depression: a meta-analysis","volume":"42","author":"Kalu","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib311","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine\/benztropine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib312","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nn.3115","article-title":"The best of times, the worst of times for psychiatric disease","volume":"15","author":"Karayiorgou","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib313","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature10763","article-title":"The contribution of bone to whole-organism physiology","volume":"481","author":"Karsenty","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib314","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.mp.4001979","article-title":"Genetics of behavioural domains across the neuropsychiatric spectrum; of mice and men","volume":"12","author":"Kas","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib315","doi-asserted-by":"crossref","first-page":"102mr3","DOI":"10.1126\/scitranslmed.3002917","article-title":"Translational neuroscience of schizophrenia: seeking a meeting of minds between mouse and man","volume":"3","author":"Kas","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib316","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euroneuro.2010.12.001","article-title":"Advances in multidisciplinary and cross-species approaches to examine the neurobiology of psychiatric disorders","volume":"21","author":"Kas","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.01.016_bib317","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00023210-200822010-00002","article-title":"Neurobiological and clinical effects of the antidepressant tianeptine","volume":"22","author":"Kasper","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib318","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.euroneuro.2006.04.005","article-title":"Pregabalin: from molecule to medicine","volume":"16","author":"Kavoussi","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib319","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1747-5341-7-2","article-title":"A brief historicity of the diagnostic and statistical manual of mental disorders: issues and implications for the future of psychiatric canon and practice","volume":"7","author":"Kawa","year":"2012","journal-title":"Philos. Ethics Humanit. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib320","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","article-title":"Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic","volume":"12","author":"Keck","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib321","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib322","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.pharmthera.2010.08.011","article-title":"Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorderes: evidence from animal models","volume":"128","author":"Kehne","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib323","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib324","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1017\/S0140525X06009095","article-title":"Resolving the paradox of common, harmful, heritable mental disorders: which evolutionary genetic models work best?","volume":"29","author":"Keller","year":"2006","journal-title":"Behav. Brain Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib325","doi-asserted-by":"crossref","unstructured":"Kempton, M.J., McGuire, P., 2015. How can neuroimaging facilitate the diagnosis and strafification of patients with psychosis? this issue, 10.1016\/j.euroneuro.2014.07.006","DOI":"10.1016\/j.euroneuro.2014.07.006"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib326","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd2796","article-title":"The influence of lead discovery strategies on the properties of drug candidates","volume":"8","author":"Keseru","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib327","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.291.21.2581","article-title":"Prevalence, severity, and unmet need for treatment of mental disorders in the world health organization world mental health surveys","volume":"291","author":"Kessler","year":"2004","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib328","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/01.jcp.0000088915.02635.e8","article-title":"Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders","volume":"23","author":"Ketter","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib329","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.drudis.2012.05.007","article-title":"Drug discovery in pharmaceutical industry: productivity challenges and trends","volume":"17","author":"Khanna","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib803","first-page":"1175","article-title":"Crystal structure of a monomeric retroviral protease solved by protein solving game players","volume":"18","author":"Khatib","year":"2011"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib330","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nsmb.2119","article-title":"Crystal structure of a monomeric retroviral protease solved by protein folding game players","volume":"18","author":"Khatib","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib331","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyg.2014.00602","article-title":"The DSM: mindful science or mindless power? a critical review","volume":"5","author":"Khoury","year":"2014","journal-title":"Front. Psychol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib332","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0364-7722(79)90070-5","article-title":"Classification of depression and the activity profile of antidepressants","volume":"3","author":"Kielholz","year":"1979","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib333","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bmj.1.5220.168","article-title":"Depression treated with imipramine: a follow-up study","volume":"1","author":"Kiloh","year":"1961","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib334","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/2051013614537818","article-title":"Vaccines against drugs of abuse: where are we now?","volume":"2","author":"Kinsey","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib335","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib336","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.biopsych.2013.07.022","article-title":"The penetrance of copy number variations for schizophrenia and developmental delay","volume":"75","author":"Kirov","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib337","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neuropharm.2014.01.013","article-title":"The role of DNA methylation in stress-related psychiatric disorders","volume":"80","author":"Klengel","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib338","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuroimage.2011.11.002","article-title":"Diagnostic neuroimaging across diseases","volume":"61","author":"Kl\u00f6ppel","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib339","doi-asserted-by":"crossref","first-page":"e90302","DOI":"10.1371\/journal.pone.0090302","article-title":"Industry-university collaborations in Canada, Japan, the UK and USA-with emphasis on publication freedom and managing the intellectual property lock-up problem","volume":"9","author":"Kneller","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib340","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pneurobio.2010.04.002","article-title":"Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases","volume":"91","author":"Knuesel","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib341","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4088\/JCP.08m04371","article-title":"Patients preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination","volume":"70","author":"Kocsis","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib342","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.neubiorev.2013.03.020","article-title":"Epigenetic dynamics in psychiatric disorders: environmental programming of neurodevelopmental processes","volume":"37","author":"Kofink","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib343","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1111\/bph.12710","article-title":"Sex differences in animal models of psychiatric disorders","volume":"171","author":"Kokras","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"1)","key":"10.1016\/j.euroneuro.2015.01.016_bib344","first-page":"CD006626","article-title":"\u201cRisperidone versus other atypical antipsychotics for schizophrenia\u201c","author":"Komossa","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib345","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrn2807","article-title":"Modelling the molecular mechanisms of synaptic plasticity using systems biology approaches","volume":"11","author":"Kotaleski","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib346","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuroscience.2013.04.042","article-title":"Decisive role of Reelin signaling during early stages of Alzheimer\u05f3s disease","volume":"246","author":"Krstic","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib347","first-page":"1135","article-title":"Treatment of depressive states with an iminodibenzyl derivative (G 22355)]","volume":"87","author":"Kuhn","year":"1957","journal-title":"Schweiz. Med. Wochenschr."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib348","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-med-050911-161945","article-title":"Psychiatry\u05f3s integration with medicine: the role of DSM-5","volume":"64","author":"Kupfer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib349","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1586\/ern.12.71","article-title":"Cognitive remediation for schizophrenia: current status, biological correlates and predictors of response","volume":"12","author":"Kurtz","year":"2012","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib350","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fendo.2014.00163","article-title":"Ghrelin-derived peptides: a link between appetite\/reward, GH axis, and psychiatric disorders?","volume":"5","author":"Labarthe","year":"2014","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib352","first-page":"631","article-title":"L\u05f3hibernation artificielle par moyens pharmacodynamique set physiques en chirurgie","volume":"67","author":"Laborit","year":"1951"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib353","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited-will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib354","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12402-010-0045-8","article-title":"The history of attention deficit hyperactivity disorder","volume":"2","author":"Lange","year":"2010","journal-title":"Atten. Defic. Hyperact. Disord."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib355","first-page":"1101","article-title":"Novel glutamatergic drugs for the treatment of mood disorders","volume":"9","author":"Lapidus","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib356","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.euroneuro.2013.01.006","article-title":"International comparative performance of mental health research, 1980\u20132011","volume":"23","author":"Larivi\u00e8re","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib807","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0021-9681(55)90090-4","article-title":"The controlled clinical trial: theory and practice","volume":"1","author":"Lasagna","year":"1955","journal-title":"J Chronic Dis."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib357","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbr.2009.11.037","article-title":"Dopamine D4-receptor modulation of cortical neuronal network activity and emotional processing: Implications for neuropsychiatric disorders","volume":"208","author":"Lauzon","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib358","doi-asserted-by":"crossref","first-page":"12165","DOI":"10.1073\/pnas.1206118109","article-title":"Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110\u03b4 inhibition as a potential therapeutic strategy","volume":"109","author":"Law","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib359","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrd3756","article-title":"Antibody-enabled small-molecule drug discovery","volume":"11","author":"Lawson","year":"2012","journal-title":"Nat. Rev. Drugs Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib360","doi-asserted-by":"crossref","DOI":"10.1038\/mp.2013.184","article-title":"P-values in genomics: apparent precision masks high uncertainly","author":"Lazzeroni","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib361","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/15622975.2010.601760","article-title":"Human endogenous retrovirus type W (HERV-W) in schizophrenia: a new avenue of research at the gene-environment interface","volume":"14","author":"Leboyer","year":"2013","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib362","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jad.2013.01.036","article-title":"Determinants of adherence to treatment in bipolar disorder: a comprehensive review","volume":"149","author":"Leclerc","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib363","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/1087057111405379","article-title":"Open innovation for phenotypic drug discovery: the PD2 assay panel","volume":"16","author":"Lee","year":"2011","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib804","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.1260497","article-title":"Mental health. Adolescent mental health-opportunity and obligation","volume":"346","author":"Lee","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib364","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature10190","article-title":"City living and urban upbringing affect neural social stress processing in humans","volume":"474","author":"Lederbogen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib365","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/archneurpsyc.1954.02320380093011","article-title":"Chlorpromazine, new inhibiting agent for psychomotor excitement and manic states","volume":"71","author":"Lehmann","year":"1954","journal-title":"Arch. Neurol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib366","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/schbul\/sbp044","article-title":"Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel","volume":"37","author":"Leifker","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib367","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","article-title":"Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects","volume":"19","author":"Leonard","year":"2004","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib368","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1017\/S1461145704004109","article-title":"Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials","volume":"7","author":"Leucht","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib369","first-page":"951","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib370","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib371","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1192\/bjp.bp.111.096594","article-title":"Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses","volume":"200","author":"Leucht","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib372","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2014.07.029","article-title":"Genetic studies of major depressive disorder: why are there no genome-wide association study findings and what can we do about it?","volume":"76","author":"Levinson","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib373","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/j.1460-9568.2012.08156.x","article-title":"Cortical circuit dysfunction and cognitive deficits in schizophrenia \u2013 implications for preemptive interventions","volume":"35","author":"Lewis","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib374","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tins.2011.10.004","article-title":"Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia","volume":"35","author":"Lewis","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib375","first-page":"CD001715","article-title":"Sertindole for schizophrenia","volume":"20","author":"Lewis","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib376","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0026-895X(25)08945-X","article-title":"In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone","volume":"41","author":"Leysen","year":"1992","journal-title":"Mol. Pharmacol."},{"issue":"Suppl.","key":"10.1016\/j.euroneuro.2015.01.016_bib377","first-page":"5","article-title":"Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity","volume":"55","author":"Leysen","year":"1994","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib378","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.1168243","article-title":"Drug discovery and natural products: end of an era or an endless frontier?","volume":"325","author":"Li","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib379","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"For the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib380","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1038\/psp.2014.7","article-title":"Prediction of efficacy of Vabicaserin, a 5-HT2C agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model","volume":"3","author":"Liu","year":"2014","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib381","first-page":"129","article-title":"A clinical and pharmacodynamics evaluation of iproniazid as a psychic energizer","volume":"8","author":"Loomer","year":"1958","journal-title":"Psychiatr. Res. Rep."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib382","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2174\/138161209788168001","article-title":"Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today","volume":"15","author":"L\u00f3pez-Mu\u00f1oz","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib383","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib384","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0893-133X(98)00075-X","article-title":"Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression","volume":"20","author":"Lotufo-Neto","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib386","first-page":"1769","article-title":"Modulation of the GABAergic pathways for the treatment of fragile X syndrome","volume":"10","author":"Lozano","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib387","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S003329170900590X","article-title":"Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials","volume":"40","author":"Lynch","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib388","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Maccaron","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib389","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nbd.2009.12.026","article-title":"The epigenetics of social adversity in early life: implications for mental health outcomes","volume":"39","author":"McGowan","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib390","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/mp.2009.80","article-title":"The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation","volume":"15","author":"McEwen","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib391","first-page":"19","article-title":"Advancing the promise of therapeutic genomic editing","author":"Maeder","year":"2014","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib392","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0161-813X(03)00102-5","article-title":"(\u2212)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties","volume":"25","author":"Magyar","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib393","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.euroneuro.2013.10.018","article-title":"Negative symptoms, past and present: a historical perspective and moving to DSM-5","volume":"24","author":"Malaspina","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib394","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrn3229","article-title":"Impaired mitochondrial function in psychiatric disorders","volume":"13","author":"Manji","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/npp.2008.173","article-title":"Removing obstacles in neuroscience drug discovery: the future path for animal models","volume":"34","author":"Marcou","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib396","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eurpsy.2011.07.006","article-title":"Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs","volume":"27","author":"Martin","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib397","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fgene.2013.00181","article-title":"Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders","volume":"4","author":"Martinez-Martinez","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib398","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/B978-0-12-385952-5.00001-4","article-title":"GPCR-interacting proteins, major players of GPCR function","volume":"62","author":"Maurice","year":"2011","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib399","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/bies.201100071","article-title":"Human pluripotent stem cells for disease modelling and drug screening","volume":"34","author":"Maury","year":"2011","journal-title":"Bioessays"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib400","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tics.2011.08.002","article-title":"Experience-dependent structural plasticity in the adult human brain","volume":"15","author":"May","year":"2011","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib401","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/0748730412456367","article-title":"Cellular circadian clocks in mood disorders","volume":"27","author":"McCarthy","year":"2012","journal-title":"J. Biol. Rhythms"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib402","doi-asserted-by":"crossref","first-page":"e42884","DOI":"10.1371\/journal.pone.0042884","article-title":"Prioritizing key resilience indicators to support coral reef management in a changing climate","volume":"7","author":"McClanahan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib403","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tins.2009.11.006","article-title":"The prairie vole: an emerging model organism for understanding the social brain","volume":"33","author":"McGraw","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib404","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/emmm.201201410","article-title":"5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia","volume":"4","author":"Meffre","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib405","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.21595","article-title":"Epigenetics and the nervous system","volume":"64","author":"Mehler","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib406","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.drudis.2012.06.015","article-title":"Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases","volume":"17","author":"Mei","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib407","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euroneuro.2008.06.003","article-title":"A regulatory Apologia \u2013 a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants","volume":"18","author":"Melander","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib408","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-4458-1-7","article-title":"Classification in psychiatry: does it deliver in schizophrenia and depression?","volume":"1","author":"Mellsop","year":"2007","journal-title":"Int. J. Ment. Health Syst."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib410","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib411","first-page":"44","article-title":"Clinical efficacy of clozapine in the treatment of schizophrenia","volume":"24","author":"Meltzer","year":"1991","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib412","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). International Suicide Prevention Trial Study Group","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib413","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2174\/138920112800784880","article-title":"Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia","volume":"13","author":"Meltzer","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib414","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib415","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.tics.2011.08.003","article-title":"Large-scale brain networks and psychopathology: a unifying triple network model","volume":"15","author":"Menon","year":"2011","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib416","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature09569","article-title":"From maps to mechanisms through neuroimaging of schizophrenia","volume":"468","author":"Meyer-Lindenberg","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib417","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn3044","article-title":"Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine","volume":"12","author":"Meyer-Lindenberg","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib418","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.tips.2006.05.004","article-title":"Antidepressants and pain","volume":"27","author":"Mic\u00f3","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib419","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev-clinpsy-032210-104601","article-title":"The economic analysis of prevention in mental health programs","volume":"7","author":"Mihalopoulos","year":"2011","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib420","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT1A) receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib421","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0301-0082(02)00009-6","article-title":"Descending control of pain","volume":"66","author":"Millan","year":"2002","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib422","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0301-0082(03)00087-X","article-title":"The neurobiology and control of anxious states","volume":"70","author":"Millan","year":"2003","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib423","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2515\/therapie:2005065","article-title":"Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies","volume":"60","author":"Millan","year":"2005","journal-title":"Therapie"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib424","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","article-title":"Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application","volume":"110","author":"Millan","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib425","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nurt.2008.10.039","article-title":"Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs","volume":"6","author":"Millan","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib426","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuropharm.2012.11.015","article-title":"An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy","volume":"68","author":"Millan","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib427","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1017\/S1461145712001496","article-title":"On \u2018polypharmacy\u2019 and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal","volume":"17","author":"Millan","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib428","doi-asserted-by":"crossref","first-page":"373","DOI":"10.31887\/DCNS.2014.16.3\/mmillan","article-title":"The epigenetic dimension of Alzheimer\u05f3s disease: causal, consequence, or curiosity?","volume":"16","author":"Millan","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib429","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib430","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.neubiorev.2013.09.012","article-title":"Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative","volume":"37","author":"Millan","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib431","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-3565(24)35260-7","volume":"292","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib432","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.euroneuro.2010.04.003","article-title":"S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine","volume":"20","author":"Millan","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib433","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0022-3565(24)29416-7","article-title":"S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine","volume":"298","author":"Millan","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib434","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","article-title":"Selective blockade of dopamine D3 vs D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis","volume":"100","author":"Millan","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib435","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.euroneuro.2014.03.008","article-title":"Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment","volume":"24","author":"Millan","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib436","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1460-9568.2000.00982.x","article-title":"Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of \u03b12-adrenergic and serotonin2C receptors: a comparison with citalopram","volume":"12","author":"Millan","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib437","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2015.01.015","article-title":"60 years of advances in neuropsychopharmacology for improving brain health: renewed hope for progress","author":"Millan","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib438","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/026988110001400202","article-title":"Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents","volume":"14","author":"Millan","year":"2000","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib439","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib440","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/embor.2009.282","article-title":"Lost in translation: the current focus on translating research into applications might be part of the natural cycle of research funding, but at what cost?","volume":"11","author":"Minogue","year":"2010","journal-title":"EMBO Rep."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib441","first-page":"515","article-title":"Lithium treatment for bipolar disorder","volume":"78","author":"Mitchell","year":"2000","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib442","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.tips.2009.01.005","article-title":"Subcellular neuropharmacology: the importance of intracellular targeting","volume":"30","author":"Miyashiro","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib443","first-page":"247","article-title":"Benzodiazepine receptors: mode of interaction of agonists and antagonists","volume":"37","author":"M\u00f6hler","year":"1983","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib444","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","article-title":"The GABA system in anxiety and depression and its therapeutic potential","volume":"62","author":"M\u00f6hler","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib445","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.300.1.2","article-title":"A new benzodiazepine pharmacology","volume":"300","author":"M\u00f6hler","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib808","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tics.2011.11.018","article-title":"Computational psychiatry","volume":"16","author":"Montague","year":"2012","journal-title":"Trends Cogn Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib446","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/YIC.0b013e3282eff7e0","article-title":"Which antidepressants have demonstrated superior efficacy? A review of the evidence","volume":"22","author":"Montgomery","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib447","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","article-title":"Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib448","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1874467210902010095","article-title":"Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr","volume":"2","author":"Monti","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib449","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2014.00112","article-title":"Neuroinflammation in the pathogenesis of Alzheimer\u05f3s disease. A rational framework for the search of novel therapeutic approaches","volume":"8","author":"Morales","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib450","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-3565(25)10792-1","article-title":"The behavioral pharmacology of olanzapine, a novel \u201catypical\u201d antipsychotic agent","volume":"262","author":"Moore","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib451","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pbb.2009.01.015","article-title":"Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence","volume":"92","author":"Moreno","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib452","first-page":"59","article-title":"Methylphenidate abuse and psychiatric side effects. Prim Care Companion","volume":"2","author":"Morton","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib1005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1037\/prj0000108","article-title":"Rising to the challenge of first episode psychosis: the NIMH Recovery After Initial Schizophrenia Episode (RAISE) initiative","volume":"37","author":"Mueser","year":"2014","journal-title":"Psychiatr. Rehabil. J."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib453","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2011.08.003","article-title":"From genes to therapeutic targets for psychiatric disorders \u2013 what to expect?","volume":"11","author":"Muglia","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib454","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/npp.2012.171","article-title":"Occupancy of brain dopamine D3 receptors and drug craving: a translational approach","volume":"38","author":"Mugnaini","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib455","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd3473","article-title":"Could pharma open its drug freezers?","volume":"10","author":"Mullard","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib456","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11920-012-0337-0","article-title":"The gut microbiome: a new frontier in autism research","volume":"15","author":"Mulle","year":"2013","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib457","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1002\/anie.201004437","article-title":"Combining independent drug classes into superior, synergistically acting hybrid molecules","volume":"49","author":"M\u00fcller-Schiffmann","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib458","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2961","article-title":"Lessons from 60 years of pharmaceutical innovation","volume":"8","author":"Munos","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib459","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1177\/0269881110372547","article-title":"Using MRI to measure drug action: caveats and new directions","volume":"25","author":"Murphy","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib460","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nrn2253","article-title":"Cannabis, the mind and society: the hash realities","volume":"8","author":"Murray","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib461","unstructured":"Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., Ezzati M., Shibuya K., Salomon J.A., Abdalla S., Aboyans V., Abraham J., Ackerman I., Aggarwal R., Ahn S.Y., Ali M.K., Alvarado M., Anderson H.R., Anderson L.M., Andrews K.G., Atkinson C., Baddour L.M., Bahalim A.N., Barker-Collo S., Barrero L.H., Bartels D.H., Bas\u00e1\u00f1ez M.G., Baxter A., Bell M.L., Benjamin E.J., Bennett D., Bernab\u00e9 E., Bhalla K., Bhandari B., Bikbov B., Bin Abdulhak A., Birbeck G., Black J.A., Blencowe H., Blore J.D., Blyth F., Bolliger I., Bonaventure A., Boufous S., Bourne R., Boussinesq M., Braithwaite T., Brayne C., Bridgett L., Brooker S., Brooks P., Brugha T.S., Bryan-Hancock C., Bucello C., Buchbinder R., Buckle G., Budke C.M., Burch M., Burney P., Burstein R., Calabria B., Campbell B., Canter C.E., Carabin H., Carapetis J., Carmona L., Cella C., Charlson F., Chen H., Cheng A.T., Chou D., Chugh S.S., Coffeng L.E., Colan S.D., Colquhoun S., Colson K.E., Condon J., Connor M.D., Cooper L.T., Corriere M., Cortinovis M., de Vaccaro K.C., Couser W., Cowie B.C., Criqui M.H., Cross M., Dabhadkar K.C., Dahiya M., Dahodwala N., Damsere-Derry J., Danaei G., Davis A., De Leo D., Degenhardt L., Dellavalle R., Delossantos A., Denenberg J., Derrett S., Des Jarlais D.C., Dharmaratne S.D., Dherani M., Diaz-Torne C., Dolk H., Dorsey E.R., Driscoll T., Duber H., Ebel B., Edmond K., Elbaz A., Ali S.E., Erskine H., Erwin P.J., Espindola P., Ewoigbokhan S.E., Farzadfar F., Feigin V., Felson D.T., Ferrari A., Ferri C.P., F\u00e8vre E.M., Finucane M.M., Flaxman S., Flood L., Foreman K., Forouzanfar M.H., Fowkes F.G., Fransen M., Freeman M.K., Gabbe B.J., Gabriel S.E., Gakidou E., Ganatra H.A., Garcia B., Gaspari F., Gillum R.F., Gmel G., Gonzalez-Medina D., Gosselin R., Grainger R., Grant B., Groeger J., Guillemin F., Gunnell D., Gupta R., Haagsma J., Hagan H., Halasa Y.A., Hall W., Haring D., Haro J.M., Harrison J.E., Havmoeller R., Hay R.J., Higashi H., Hill C., Hoen B., Hoffman H., Hotez P.J., Hoy D., Huang J.J., Ibeanusi S.E., Jacobsen K.H., James S.L., Jarvis D., Jasrasaria R., Jayaraman S., Johns N., Jonas J.B., Karthikeyan G., Kassebaum N., Kawakami N., Keren A., Khoo J.P., King C.H., Knowlton L.M., Kobusingye O., Koranteng A., Krishnamurthi R., Laden F., Lalloo R., Laslett L.L., Lathlean T., Leasher J.L., Lee Y.Y., Leigh J., Levinson D., Lim S.S., Limb E., Lin J.K., Lipnick M., Lipshultz S.E., Liu W., Loane M., Ohno S.L., Lyons R., Mabweijano J., MacIntyre M.F., Malekzadeh R., Mallinger L., Manivannan S., Marcenes W., March L., Margolis D.J., Marks G.B., Marks R., Matsumori A., Matzopoulos R., Mayosi B.M., McAnulty J.H., McDermott M.M., McGill N., McGrath J., Medina-Mora M.E., Meltzer M., Mensah G.A., Merriman T.R., Meyer A.C., Miglioli V., Miller M., Miller T.R., Mitchell P.B., Mock C., Mocumbi A.O., Moffitt T.E., Mokdad A.A., Monasta L., Montico M., Moradi-Lakeh M., Moran A., Morawska L., Mori R., Murdoch M.E., Mwaniki M.K., Naidoo K., Nair M.N., Naldi L., Narayan K.M., Nelson P.K., Nelson R.G., Nevitt M.C., Newton C.R., Nolte S., Norman P., Norman R., O\u05f3Donnell M., O\u05f3Hanlon S., Olives C., Omer S.B., Ortblad K., Osborne R., Ozgediz D., Page A., Pahari B., Pandian J.D., Rivero A.P., Patten S.B., Pearce N., Padilla R.P., Perez-Ruiz F., Perico N., Pesudovs K., Phillips D., Phillips M.R., Pierce K., Pion S., Polanczyk G.V., Polinder S., Pope CA 3rd, Popova S., Porrini E., Pourmalek F., Prince M., Pullan R.L., Ramaiah K.D., Ranganathan D., Razavi H., Regan M., Rehm J.T., Rein D.B., Remuzzi G., Richardson K., Rivara F.P., Roberts T., Robinson C., De Le\u00f2n F.R., Ronfani L., Room R., Rosenfeld L.C., Rushton L., Sacco R.L., Saha S., Sampson U., Sanchez-Riera L., Sanman E., Schwebel D.C., Scott J.G., Segui-Gomez M., Shahraz S., Shepard D.S., Shin H., Shivakoti R., Singh D., Singh G.M., Singh J.A., Singleton J., Sleet D.A., Sliwa K., Smith E., Smith J.L., Stapelberg N.J., Steer A., Steiner T., Stolk W.A., Stovner L.J., Sudfeld C., Syed S., Tamburlini G., Tavakkoli M., Taylor H.R., Taylor J.A., Taylor W.J., Thomas B., Thomson W.M., Thurston G.D., Tleyjeh I.M., Tonelli M., Towbin J.A., Truelsen T., Tsilimbaris M.K., Ubeda C., Undurraga E.A., van der Werf M.J., van Os J., Vavilala M.S., Venketasubramanian N., Wang M., Wang W., Watt K., Weatherall D.J., Weinstock M.A., Weintraub R., Weisskopf M.G., Weissman M.M., White R.A., Whiteford H., Wiebe N., Wiersma S.T., Wilkinson J.D., Williams H.C., Williams S.R., Witt E., Wolfe F., Woolf A.D., Wulf S., Yeh P.H., Zaidi A.K., Zheng Z.J., Zonies D., Lopez A.D., AlMazroa M.A., Memish Z.A.. 2010. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2197-2223."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib462","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1517\/14656566.2014.947960","article-title":"Sertindole in schizophrenia: efficacy and safety issues","volume":"15","author":"Muscatello","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib463","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ddstr.2011.10.003","article-title":"Orphan\/rare drug discovery through drug repositioning","volume":"8","author":"Muthyala","year":"2011","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib464","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.schres.2014.04.041","article-title":"Neuroinflammation and white matter pathology in schizophrenia: systematic review","volume":"161","author":"Najjar","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib465","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pnpbp.2014.08.018","article-title":"Schizophrenia and the gut-brain axis","volume":"56","author":"Nemani","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib466","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd3822","article-title":"Down\u05f3s syndrome and Alzheimer\u05f3s disease: towards secondary prevention","volume":"11","author":"Ness","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib467","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrd3799","article-title":"Revisiting lab-on-a-chip technology for drug discovery","volume":"11","author":"Neuzil","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib468","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib469","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1515\/revneuro-2014-0005","article-title":"The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia","volume":"25","author":"Nikiforuk","year":"2014","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib470","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5694\/j.1326-5377.1951.tb68249.x","article-title":"The lithium treatment of maniacal psychosis","volume":"2","author":"Noack","year":"1951","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib471","doi-asserted-by":"crossref","first-page":"589524","DOI":"10.1155\/2012\/589524","article-title":"Animal models of psychiatric disorders that reflect human copy number variation","volume":"2012","author":"Nomura","year":"2012","journal-title":"Neural Plast."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib472","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","article-title":"Potential for primary prevention of Alzheimer\u05f3s disease: an analysis of population-based data","volume":"13","author":"Norton","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib473","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fncir.2013.00079","article-title":"Toward developmental models of psychiatric disorders in zebrafish","volume":"7","author":"Norton","year":"2013","journal-title":"Front. Neural Circuits"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib474","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.tips.2011.08.004","article-title":"Allo-network drugs: harnessing allostery in cellular networks","volume":"32","author":"Nussinov","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib475","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.puhe.2013.08.016","article-title":"An ecological study investigating the association between access to urban green space and mental health","volume":"127","author":"Nutsford","year":"2013","journal-title":"Public Health"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib476","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coph.2011.12.001","article-title":"Massive overuse of appropriate medical intervention? The modern-day use of antidepressants","volume":"12","author":"Nutt","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib477","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.euroneuro.2011.05.004","article-title":"ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin","volume":"21","author":"Nutt","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib478","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1017\/S1461145713000680","article-title":"Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR","volume":"16","author":"Nyberg","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib479","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s11524-013-9852-5","article-title":"External built residential environment characteristics that affect mental health of adults","volume":"91","author":"Ochodo","year":"2014","journal-title":"J. Urban Health"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib480","first-page":"i1","article-title":"Consensus document on European brain research","volume":"77","author":"Olesen","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib481","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.13m08834","article-title":"Trends in office-based mental health care provided by psychiatrists and primary care physicians","volume":"75","author":"Olfson","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib482","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","article-title":"Drug repurposing from an academic perspective","volume":"8","author":"Oprea","year":"2011","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib483","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1358\/dot.2006.42.4.970842","article-title":"Ramelteon: profile of a new sleep-promoting medication","volume":"42","author":"Owen","year":"2006","journal-title":"Drugs Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib484","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1358\/dot.2007.43.9.1133188","article-title":"Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety","volume":"43","author":"Owen","year":"2007","journal-title":"Drugs Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib485","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/jpet.102.034280","article-title":"Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist","volume":"302","author":"Page","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib486","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib487","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib488","doi-asserted-by":"crossref","first-page":"533","DOI":"10.31887\/DCNS.2010.12.4\/jpanksepp","article-title":"Affective neuroscience of the emotional brain mind: evolutionary perspectives and implications for understanding depression","volume":"12","author":"Panksepp","year":"2010","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib489","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/hlca.194402701222","article-title":"La preparazione di piridile piridilarilac \u2013 tonitrilie di alcuni prodotti transformazione (part la)","volume":"2","author":"Panizzon","year":"1944","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib490","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.euroneuro.2007.07.005","article-title":"A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder","volume":"18","author":"Papakostas","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib491","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.neuropharm.2011.04.025","article-title":"Mouse models of genetic effects on cognition: relevance to schizophrenia","volume":"62","author":"Papaleo","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib492","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.addr.2007.03.008","article-title":"shRNA and siRNA delivery to the brain","volume":"59","author":"Pardridge","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib493","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1185\/03007995.2013.770731","article-title":"Comprehensive review of generalized anxiety disorder in primary care in Europe","volume":"29","author":"Parmentier","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib494","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.schres.2009.12.003","article-title":"Cognitive remediation therapy in schiozophrenia: cost-effectiveness analysis","volume":"20","author":"Patel","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib495","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1176\/ps.2007.58.4.449","article-title":"Best practices: the development of the social cognition and interaction training program for schizophrenia spectrum disorders","volume":"58","author":"Penn","year":"2007","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib496","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.tips.2011.07.002","article-title":"Systems genetics for drug target discovery","volume":"32","author":"Penrod","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib497","unstructured":"Perez-Rodriguez, M., Mahon, K., Russo, M., Ungar, A.K., Burdick, K.E., 2014. Eur Neuropsychopharmacol., in press. HYPERLINK \"\/pubmed\/25153535\"Oxytocin and social cognition in affective and psychotic disorders. 10.1016\/j.euroneuro.2014.07.012."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib498","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1038\/tp.2012.125","article-title":"Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder","volume":"2","author":"Perron","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.01.016_bib499","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/gb-2010-11-5-206","article-title":"Between a chicken and a grape; estimating the number of human genes","volume":"11","author":"Pertea","year":"2010","journal-title":"Genome Biol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib500","first-page":"1","article-title":"The six most essential questions in psychiatric diagnosis: a pluralogue. Part 4: General conclusion","volume":"7","author":"Phillips","year":"2012","journal-title":"Philos. Ethics Humanit. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib501","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.biopsych.2013.01.021","article-title":"Glutamate-based antidepressants: preclinical psychopharmacology","volume":"73","author":"Pilc","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib502","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11598460-000000000-00000","article-title":"Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials","volume":"51","author":"Pilla Reddy","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib503","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/14656566.2014.914493","article-title":"An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder","volume":"15","author":"Pizarro","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib504","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0022-3565(25)11640-6","article-title":"Serotonin as a mediator of reserpine action in brain","volume":"116","author":"Pletscher","year":"1956","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib505","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.neuroimage.2012.01.129","article-title":"Test\u2013retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery","volume":"60","author":"Plichta","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib506","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/mp.2013.136","article-title":"Imaging glutamate in schizophrenia: review of findings and implications for drug discovery","volume":"19","author":"Poels","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib507","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1192\/bjp.bp.105.015263","article-title":"Psychological effects of ketamine in healthy volunteers. Phenomenological study","volume":"189","author":"Pomarol-Clotet","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib508","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00213-013-3330-3","article-title":"Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development","volume":"231","author":"Pop","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib509","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.biopsych.2006.05.008","article-title":"Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?","volume":"59","author":"Powell","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib510","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3649","article-title":"Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap","volume":"11","author":"Pratt","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib511","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0447.1995.tb05923.x","article-title":"Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders","volume":"386","author":"Priest","year":"1995","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib512","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrd3439-c1","article-title":"Believe it or not: how much can we rely on published data on potential drug targets?","volume":"10","author":"Prinz","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib513","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature12975","article-title":"A polygenic burden of rare disruptive mutations in schizophrenia","volume":"506","author":"Purcell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib514","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bph.12534","article-title":"Properties of human brain sodium channel \u03b1-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine","volume":"171","author":"Qiao","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib515","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bandc.2012.02.006","article-title":"Training the brain: fact and fad in cognitive and behavioral remediation","volume":"79","author":"Rabipour","year":"2012","journal-title":"Brain Cogn."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib516","first-page":"7","article-title":"Pharmacology of chlordiazepoxide (\u2018Librium\u2019)","volume":"22","author":"Randall","year":"1961","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib517","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/wps.20028","article-title":"Pediatric psychopharmacology: too much or too little?","volume":"12","author":"Rapoport","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib518","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.brainresrev.2009.06.003","article-title":"Bipolar disorder and mechanisms of action of mood stabilizers","volume":"61","author":"Rapoport","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib519","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd3478","article-title":"Trends in the exploitation of novel drug targets","volume":"10","author":"Rask-Andersen","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib520","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/JCP.0b013e31823608ca","article-title":"Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder","volume":"31","author":"Ratti","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib521","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1469-185X.2007.00010.x","article-title":"Integrating animal temperament within ecology and evolution","volume":"82","author":"R\u00e9ale","year":"2007","journal-title":"Biol. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib522","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/507288a","article-title":"NIH rethinks psychiatry trials","volume":"507","author":"Reardon","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib523","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddstr.2011.09.007","article-title":"Drug repurposing through non-hypothesis driven phenotypic screening","volume":"8","author":"Reaume","year":"2011","journal-title":"Drug Discov. Today Ther. Strategy"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib524","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/mp.2013.156","article-title":"Evidence that duplications of 22q11.2 protect against schizophrenia","volume":"19","author":"Rees","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib525","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/wps.20050","article-title":"The DSM-5: classification and criteria changes","volume":"12","author":"Regier","year":"2013","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib526","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.neuropharm.2011.01.024","article-title":"The role of neurexins in schizophrenia and autistic spectrum disorder","volume":"62","author":"Reichelt","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib527","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1017\/S1461145712001095","article-title":"Improving myelin\/oligodendrocyte-related dysfunction: a new mechanism of antipsychotics in the treatment of schizophrenia","volume":"16","author":"Ren","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib528","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2014.08.002","article-title":"Animal models of social anxiety disorder and their validity criteria","volume":"114","author":"R\u00e9us","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib529","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1038\/npp.2014.121","article-title":"Cellular and behavioral outcomes of dorsal striatonigral neuron ablation: new insights into striatal functions","volume":"39","author":"R\u00e9vy","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib1006","doi-asserted-by":"crossref","unstructured":"Richards, T., Montori, V.M., Godlee, F., Lapsley, P., Paul, D., 2013. Let the patient revolution begin. British Medical Journal, May 14;346:f2614. 10.1136\/bmj.f2614.","DOI":"10.1136\/bmj.f2614"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib530","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.puhe.2013.01.004","article-title":"Role of physical activity in the relationship between urban green space and health","volume":"127","author":"Richardson","year":"2013","journal-title":"Public Health"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib531","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1001\/jama.1959.03010300023005","article-title":"Evaluation of tranquilizing drugs in medical outpatients","volume":"171","author":"Rickels","year":"1959","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib532","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ng.2742","article-title":"Genome-wide association analysis identifies 13 new risk loci for schizophrenia","volume":"45","author":"Ripke","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib533","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-clinpsy-050212-185535","article-title":"Neuroimaging and other biomarkers for Alzheimer\u05f3s disease: the changing landscape of early detection","volume":"9","author":"Risacher","year":"2013","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib534","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jpsychires.2010.09.007","article-title":"Neural correlates of emotional processing in depression: changes with cognitive behavioral therapy and predictors of treatment response","volume":"45","author":"Ritchey","year":"2011","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib535","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tics.2011.11.009","article-title":"Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry","volume":"16","author":"Robbins","year":"2012","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib536","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/2327-6924.12094","article-title":"Prostate-specific antigen screening: a critical review of current research and guidelines","volume":"26","author":"Robinson","year":"2014","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib537","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psychres.2014.04.018","article-title":"Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting","volume":"218","author":"Rocca","year":"2014","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib538","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tree.2012.04.007","article-title":"Global disparity in the resilience of coral reefs","volume":"27","author":"Roff","year":"2012","journal-title":"Trends Ecol. Evol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib539","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/eci.12255","article-title":"Update on the efficacy of statin treatment in acute coronary syndrome","volume":"44","author":"Rosa","year":"2014","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib540","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(67)90084-2","article-title":"Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents","volume":"2","author":"Ross","year":"1967","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib541","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","article-title":"Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors","volume":"268","author":"Roth","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib542","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1176\/ps.2010.61.11.1099","article-title":"Web-based psychoeducational intervention for persons with schizophrenia and their supporters: one-year outcomes","volume":"61","author":"Rotondi","year":"2010","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib543","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib544","first-page":"82","article-title":"Preventive pharmacological treatment \u2013 an evolving new concept in schizophrenia","volume":"48","author":"Sabbag","year":"2011","journal-title":"Isr. J. Psychiatr. Relat. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib545","doi-asserted-by":"crossref","unstructured":"Sacks, S., Fisher, M., Garrett, C., Alexander, P., Holland, C., Rose, D., Hooker, C., Vinogradov, S., 2013. Combining computerized social cognitive training with neuroplasticity-based auditory training in schizophrenia. Clin. Schizophr. Relat. Psychoses 7, 78-86A.","DOI":"10.3371\/CSRP.SAFI.012513"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib546","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrmicro2395","article-title":"A hitchhiker\u05f3s guide to the nervous system: the complex journey of viruses and toxins","volume":"8","author":"Salinas","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib547","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/cap.2013.0028","article-title":"A review of the rationale and clinical utilization of \u03b12-adrenoceptor agonists for the treatment of attention-deficit\/hyperactivity and related disorders","volume":"23","author":"Sallee","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib548","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.drudis.2012.10.010","article-title":"Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift","volume":"18","author":"Sams-Dodd","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib549","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/amiajnl-2012-001275","article-title":"Pharmacogenomics in the pocket of every patient? A prototype based on quick response codes","volume":"20","author":"Samwald","year":"2013","journal-title":"J. Am. Med. Inform Assoc."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib550","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib551","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-012-0026-x","article-title":"Lurasidone: in the treatment of schizophrenia","volume":"27","author":"Sanford","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib552","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00023210-200418001-00004","article-title":"The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents","volume":"18","author":"Sanger","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib553","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/bmj.1.5483.322","article-title":"Treatment of anxiety states by antidepressant drugs","volume":"1","author":"Sargant","year":"1962","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib554","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.euroneuro.2011.04.002","article-title":"Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence","volume":"21","author":"Sarris","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib555","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv042","article-title":"Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP think-tank","author":"Scarr","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib556","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.neubiorev.2008.08.003","article-title":"Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders","volume":"33","author":"Scattoni","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib557","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11920-012-0261-3","article-title":"Functional outcomes in schizophrenia: employment status as a metric of treatment outcome","volume":"14","author":"Schennach","year":"2012","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib558","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1176\/ajp.122.5.509","article-title":"The catecholamine hypothesis of affective disorders: a review of supporting evidence","volume":"122","author":"Schildkraut","year":"1965","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib559","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hlca.19540370211","article-title":"\u00dbber Derivate des Iminobenzyls","volume":"37","author":"Schindler","year":"1954","journal-title":"Helvet. Chim. Acta"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib560","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.drudis.2014.06.011","article-title":"Academic drug discovery centres: the economic and organisational sustainability of an emerging model","volume":"19","author":"Schultz-Kirkegaard","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib561","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib562","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/0269881111431748","article-title":"The hidden third: improving outcome in treatment-resistant depression","volume":"26","author":"Schlaepfer","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib563","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/B978-0-444-53497-2.00018-8","article-title":"Deep brain stimulation for major depression","volume":"116","author":"Schlaepfer","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib564","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/jnc.12460","article-title":"Genomic editing opens new avenues for zebrafish as a model for neurodegeneration","volume":"127","author":"Schmid","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib565","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd3139","article-title":"Virtual screening; an endless staircase?","volume":"9","author":"Schneider","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib566","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib567","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/jnnp.17.4.250","article-title":"The treatment of manic psychoses by the administration of lithium salts","volume":"17","author":"Schou","year":"1954","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib568","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ejhg.2013.79","article-title":"Controlling complexity: the clinical relevance of mouse complex genetics","volume":"21","author":"Schughart","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib569","first-page":"5","article-title":"Stratified medicine for mental disorders","volume":"24","author":"Schumann","year":"2014"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib570","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.drudis.2011.05.006","article-title":"A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices","volume":"16","author":"Schwarz","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib571","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/brain.2013.0168","article-title":"Anti-correlated cortical networks of intrinsic connectivity in the rat brain","volume":"3","author":"Schwarz","year":"2013","journal-title":"Brain Connect."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.01.016_bib572","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","article-title":"Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity","volume":"275","author":"Seeger","year":"1995","journal-title":"J. Pharmacol. Exp.Therap."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib573","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib574","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1073\/pnas.72.11.4376","article-title":"Brain receptors for antipsychotic drugs and dopamine: direct binding assays","volume":"72","author":"Seeman","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib575","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/embor.2009.278","article-title":"System crash (Science and finance: same symptoms, same dangers?)","volume":"11","author":"S\u00e9galat","year":"2010","journal-title":"EMBO Rep."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib576","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-0033-1363258","article-title":"Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics","volume":"47","author":"Selle","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib577","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib578","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1192\/bjp.bp.108.050187","article-title":"Mental health research priorities in low- and middle-income countries of Africa, Asia, Latin America and the Caribbean","volume":"195","author":"Sharan","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib579","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pneurobio.2010.04.004","article-title":"Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression","volume":"91","author":"Shelton","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib580","first-page":"S106","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator-referenced, multicentre trial of vabicaserin in subjects with acute exacerbation of schizophrenia","volume":"36","author":"Shen","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib581","first-page":"17","article-title":"CNS sites cooperate to detect duplicate subjects with a clinical trial subject registry. Innov","volume":"10","author":"Shiovitz","year":"2013","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib582","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejphar.2009.10.021","article-title":"Major depression cognitive dysfunction and Alzheimer\u05f3s disease: is there a link?","volume":"626","author":"Sierksma","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib583","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nature08855","article-title":"Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia","volume":"464","author":"Sigurdsson","year":"2010","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.euroneuro.2015.01.016_bib584","first-page":"143","article-title":"Network medicine approaches to the genetics of complex diseases","volume":"2012","author":"Silverman","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib585","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00335-013-9476-9","article-title":"The NIMH research domain criteria (DRoC) project: implications for genetics research","volume":"25","author":"Simmons","year":"2014","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib586","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ddstr.2006.10.010","article-title":"Triple reuptake inhibitors as antidepressants","volume":"3","author":"Skolnick","year":"2006","journal-title":"Drug Discov. Today Ther. Strat."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib587","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol."},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib588","first-page":"9","article-title":"The great neuro-pipeline brain drain (and why big pharma hasn\u05f3t given up on CNS disorders)","author":"Skripka-Serry","year":"2013","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib589","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd4155","article-title":"Bringing together the academic drug discovery community","volume":"12","author":"Slusher","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib590","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S1734-1140(13)71518-4","article-title":"Glial degeneration as a model of depression","volume":"65","author":"Smia\u0142owska","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib591","first-page":"131","article-title":"Repositioned drugs: integrating intellectual property and regulatory strategies","volume":"8","author":"Smith","year":"2011","journal-title":"Drug Discov. Today: Ther. Strategy"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib592","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nrm1529","article-title":"Viral hijacking of G-protein-coupled-receptor signalling networks","volume":"5","author":"Sodhi","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib593","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.neuron.2010.03.007","article-title":"Social interactions in \u201csimple\u201d model systems","volume":"65","author":"Sokolowski","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib594","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrmicro2395","article-title":"A hitchhiker\u05f3s guide to the nervous system: the complex journey of viruses and toxins","volume":"8","author":"Salinas","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib595","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychires.2013.06.020","article-title":"D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions","volume":"47","author":"Smits","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib596","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.cell.2013.05.002","article-title":"Dynamics of hippocampal neurogenesis in adult humans","volume":"153","author":"Spalding","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib597","first-page":"53","article-title":"A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder","volume":"46","author":"Stark","year":"1985","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib598","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.psychres.2012.12.005","article-title":"Efficacy of social cognition remediation programs targeting facial affect recognition deficits in schizophrenia: a review and consideration of high-risk samples and sex differences","volume":"206","author":"Statucka","year":"2013","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib599","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-014-3836-3","article-title":"Editorial: Preclinical data reproducibility for R&D \u2013 the challenge for neuroscience","volume":"237","author":"Steckler","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib600","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/070674371305801202","article-title":"What is a mental disorder? A perspective from cognitive-affective science","volume":"58","author":"Stein","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib601","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.2294","article-title":"Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression","volume":"28","author":"Stein","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib602","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/02791072.1983.10472118","article-title":"The benzodiazepine story","volume":"15","author":"Sternbach","year":"1983","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib603","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euroneuro.2010.06.011","article-title":"The EU paediatric regulation: effects on paediatric psychopharmacology in Europe","volume":"21","author":"Stoyanova-Beninska","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib604","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/nedt.2007.3.2.237","article-title":"The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic","volume":"3","author":"Strawn","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib605","first-page":"27","article-title":"Bradley\u05f3s Benzedrine studies on children with behavioral disorders","volume":"84","author":"Strohl","year":"2011","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib606","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.neuron.2011.12.024","article-title":"Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia","volume":"73","author":"Subramaniam","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib607","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2012.06.012","article-title":"The presynaptic active zone","volume":"75","author":"S\u00fcdhof","year":"2012","journal-title":"Neuron"},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib608","first-page":"22","article-title":"In it for the long haul: vector mediated therapeutics based upon DNA-directed RNA interference","author":"Suhy","year":"2014","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib609","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/mp.2009.80","article-title":"The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation","volume":"15","author":"Svenningsson","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib610","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/npp.2011.195","article-title":"Beyond antipsychotics: pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia","volume":"37","author":"Swerdlow","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"Fall","key":"10.1016\/j.euroneuro.2015.01.016_bib611","first-page":"33","article-title":"Opportunities for phenotypic screening in drug discovery","author":"Swinney","year":"2014","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib612","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib613","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2014.01.009","article-title":"Epigenetics, a key for unlocking complex CNS disorders? Therapeutic implications","author":"Szyf","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib614","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1467-8624.2012.01793.x","article-title":"DNA methylation: a mechanism for embedding early life experiences in the genome","volume":"84","author":"Szyf","year":"2013","journal-title":"Child Dev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib615","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrn3464","article-title":"Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders","volume":"14","author":"Tabares-Seisdedos","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib616","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00441-013-1694-7","article-title":"Touching on translation","volume":"354","author":"Talpos","year":"2013","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib617","first-page":"e1001326","article-title":"Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis","volume":"9","author":"Tansey","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib618","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1517\/17460441.2013.815163","article-title":"The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia","volume":"8","author":"Tarazi","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib619","doi-asserted-by":"crossref","first-page":"g1888","DOI":"10.1136\/bmj.g1888","article-title":"Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies","volume":"348","author":"Taylor","year":"2014","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib620","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrd2410","article-title":"Target deconvolution strategies in drug discovery","volume":"6","author":"Terstappen","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib621","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression","volume":"26","author":"Thase","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib622","first-page":"11","article-title":"Preliminary evaluation of Librium (Ro5-0690) in the treatment of anxiety reactions","volume":"21","author":"Tobin","year":"1960","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib623","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2471\/BLT.08.054353","article-title":"Setting priorities for global mental health research","volume":"87","author":"Tomlinson","year":"2009","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib624","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/2042098613505614","article-title":"Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain","volume":"5","author":"Toth","year":"2014","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib625","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpsychires.2011.09.003","article-title":"Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Tran","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib627","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/10673229.2011.586551","article-title":"Genes, environment, and individual differences in responding to treatment for depression","volume":"19","author":"Uher","year":"2011","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib628","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.neuropharm.2011.02.021","article-title":"Induced pluripotent stem cells: a new tool to confront the challenge of neuropsychiatric disorders","volume":"60","author":"Vaccarino","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib629","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2011.09.007","article-title":"Drosophila strategies to study psychiatric disorders","volume":"92","author":"Van Alphen","year":"2013","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib630","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.autrev.2013.10.016","article-title":"Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system","volume":"13","author":"Van Coevorden-Hameete","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib631","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11065-014-9248-7","article-title":"Brain networks in schizophrenia","volume":"24","author":"Van den Heuvel","year":"2014","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib632","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/NDT.S59958","article-title":"Towards Horizon 2020: challenges and advances for clinical mental health research \u2013 outcome of an expert survey","volume":"10","author":"Van der Feltz-Cornelis","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib633","first-page":"492","article-title":"The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs","volume":"160","author":"Van Rossum","year":"1966","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib634","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0924-977X(96)00038-7","article-title":"Cholecystokinin in anxiety","volume":"6","author":"Van Megen","year":"1996","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib635","doi-asserted-by":"crossref","first-page":"e98348","DOI":"10.1371\/journal.pone.0098348","article-title":"Oral medicines for children in the European paediatric investigation plans","volume":"4","author":"Van Riet-Nales","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib809","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tins.2008.12.007","article-title":"Exercise and the brain: something to chew on","volume":"32","author":"Van Praag","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib636","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1747-5341-6-1","article-title":"Defining mental disorder. Exploring the natural function approach. 2011","volume":"6","author":"Varga","year":"2011","journal-title":"Philos. Ethics Humanit. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib637","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/npp.2014.232","article-title":"Intervention in the context of development: pathways toward new treatments","volume":"40","author":"Veenstra-VanderWeele","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib638","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejphar.2008.02.084","article-title":"Twenty of dopamine research: individual differences in the response of accumbal dopamine to environmental and pharmacological challenges","volume":"585","author":"Verheij","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib639","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40263-013-0073-y","article-title":"Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis","volume":"27","author":"Vieta","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib640","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/npp.2011.251","article-title":"Cognitive training for impaired neural systems in neuropsychiatric illness","volume":"37","author":"Vinogradov","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib1008","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1523\/JNEUROSCI.4461-11.2012","article-title":"Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder","volume":"32","author":"Volkow","year":"2012","journal-title":"J Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib641","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/schbul\/sbt079","article-title":"White matter microstructure in individuals at clinical high risk of psychosis: a whole-brain diffusion tensor imaging study","volume":"40","author":"Von Hohenberg","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib642","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of drug-like properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib805","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI61398","article-title":"A mitochondrial bioenergetics etiology of disease","volume":"123","author":"Wallace","year":"2013","journal-title":"J Clin Invest."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib643","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nn.3420","article-title":"Histone deacetylase inhibitors facilitate partner preference formation in female prairie voles","volume":"16","author":"Wang","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib644","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrg2884","article-title":"Analysing biological pathways in genome-wide association studies","volume":"11","author":"Wang","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib645","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/10673229.2011.599185","article-title":"The relevance of Caenorhabditis elegans genetics for understanding human psychiatric disease","volume":"19","author":"Wang","year":"2011","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib810","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.neuron.2014.10.018","article-title":"Computational psychiatry","volume":"84","author":"Wang","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib646","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jbtep.2009.10.003","article-title":"Online cognitive behavioral therapy and problem-solving therapy for depressive symptoms: exploring mechanisms of change","volume":"41","author":"Warmerdam","year":"2010","journal-title":"J. Behav. Ther. Exp. Psychiatr."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib647","first-page":"7","article-title":"Mirtazapine versus other antidepressive agents for depression","author":"Watanabe","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib648","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1038\/tp.2013.119","article-title":"Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application","volume":"4","author":"Watkins","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib649","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/npp.2011.254","article-title":"Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex","volume":"37","author":"Watson","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib650","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.brat.2013.05.003","article-title":"Convergence and divergence in the delivery of cognitive therapy in two randomized clinical trials","volume":"51","author":"Webb","year":"2013","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib651","first-page":"678","article-title":"Point: hypotheses first","volume":"464","author":"Weinberg","year":"2010"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib652","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.autrev.2012.10.013","article-title":"Alzheimer\u05f3s disease and Down\u05f3s syndrome: treating two paths to dementia","volume":"12","author":"Weksler","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib653","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(12)61552-9","article-title":"Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomized controlled trial","volume":"381","author":"Wiles","year":"2013","journal-title":"Lancet"},{"issue":"Winter","key":"10.1016\/j.euroneuro.2015.01.016_bib654","first-page":"28","article-title":"Informatics the same old problems, just bigger","volume":"14","author":"Williams","year":"2013","journal-title":"Drug Discov. World"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib655","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.euroneuro.2013.11.008","article-title":"Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia","volume":"24","author":"Wilson","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib656","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2014.02.003","article-title":"Risk genes for schizophrenia: translational opportunities for drug discovery","volume":"143","author":"Winchester","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib657","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib658","first-page":"171","article-title":"Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors","volume":"2","author":"Wong","year":"1990","journal-title":"Acta Pharm. Nord."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib659","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrd1821","article-title":"Case history: the discovery of fluoxetine hydrochloride (Prozac)","volume":"4","author":"Wong","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib660","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pharmthera.2010.02.001","article-title":"The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action","volume":"126","author":"Wong","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib661","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/clpt.2010.28","article-title":"Precompetitive research: a new prescription for drug development?","volume":"87","author":"Woodcock","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib662","doi-asserted-by":"crossref","first-page":"a006346","DOI":"10.1101\/cshperspect.a006346","article-title":"Inflammation in Alzheimer disease \u2013 a brief review of the basic science and clinical literature","volume":"2","author":"Wyss-Coray","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib663","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.2001.tb03656.x","article-title":"The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo","volume":"939","author":"Youdim","year":"2001","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib665","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib666","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib667","first-page":"427","article-title":"Action of isonicotinic acid hydrazide and related compounds on enzymes involved in the autonomic nervous system","volume":"106","author":"Zeller","year":"1952","journal-title":"J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib664","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbu136","article-title":"Heterogeneity of structural brain changes in subtypes of schizophrenia revealed using magnetic resonance imaging pattern analysis","volume":"41","author":"Zhang","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib668","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.psych.60.110707.163625","article-title":"Epigenetics and the environmental regulation of the genome and its function","volume":"61","author":"Zhang","year":"2010","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib669","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.drudis.2009.02.008","article-title":"Medicinal chemistry strategies in follow-on drug discovery","volume":"14","author":"Zhao","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2015.01.016_bib670","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1087057114533146","article-title":"Integrating high-content analysis into a multiplexed screening approach to identify and characterize GPCR agonists","volume":"19","author":"Zhu","year":"2014","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib671","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/schbul\/sbs135","article-title":"The myth of schizophrenia as a progressive brain disease","volume":"39","author":"Zipursky","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2015.01.016_bib672","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.euroneuro.2013.08.004","article-title":"A proposal for an updated neuropsychopharmacological nomenclature","volume":"24","author":"Zohar","year":"2014","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T09:38:02Z","timestamp":1747561082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":684,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0924977X15000176"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.01.016","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725456759.793528754","asserted-by":"object"}]},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}